MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Search

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

170.81 0.46

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

166.91

Max

172.86

Galvenie mērījumi

By Trading Economics

Ienākumi

27M

53M

Pārdošana

48M

1B

P/E

Sektora vidējais

592.3

36.442

Peļņas marža

5.105

Darbinieki

18,700

EBITDA

37M

221M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+7.74% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

150M

8.4B

Iepriekšējā atvēršanas cena

170.35

Iepriekšējā slēgšanas cena

170.81

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. okt. 23:25 UTC

Galvenie tirgus virzītāji

Salesforce Rises on New FY30 Financial Targets

2025. g. 15. okt. 18:52 UTC

Peļņas
Galvenie tirgus virzītāji

Prologis Shares Gain on Raised Outlook, Data Center Growth

2025. g. 15. okt. 18:30 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software to Buy U.K.'s Tecvia Holding

2025. g. 15. okt. 17:19 UTC

Iegādes, apvienošanās, pārņemšana

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

2025. g. 15. okt. 17:11 UTC

Iegādes, apvienošanās, pārņemšana

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

2025. g. 15. okt. 23:48 UTC

Tirgus saruna

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

2025. g. 15. okt. 23:38 UTC

Tirgus saruna

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025. g. 15. okt. 22:37 UTC

Tirgus saruna

Economic Stars Are Aligning for RBA -- Market Talk

2025. g. 15. okt. 21:44 UTC

Peļņas

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

2025. g. 15. okt. 20:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 15. okt. 20:44 UTC

Iegādes, apvienošanās, pārņemšana

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

2025. g. 15. okt. 20:44 UTC

Iegādes, apvienošanās, pārņemšana

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

2025. g. 15. okt. 20:43 UTC

Iegādes, apvienošanās, pārņemšana

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

2025. g. 15. okt. 20:34 UTC

Peļņas

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

2025. g. 15. okt. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

2025. g. 15. okt. 20:17 UTC

Iegādes, apvienošanās, pārņemšana

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

2025. g. 15. okt. 19:06 UTC

Peļņas

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

2025. g. 15. okt. 19:04 UTC

Tirgus saruna

Oil Futures Post Back-to-Back Losses -- Market Talk

2025. g. 15. okt. 18:46 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

2025. g. 15. okt. 18:23 UTC

Peļņas

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

2025. g. 15. okt. 17:37 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

2025. g. 15. okt. 17:34 UTC

Tirgus saruna

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

2025. g. 15. okt. 16:57 UTC

Peļņas

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

2025. g. 15. okt. 16:51 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica Doesn't Disclose Financial Details

2025. g. 15. okt. 16:50 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

2025. g. 15. okt. 16:49 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

2025. g. 15. okt. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

2025. g. 15. okt. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

2025. g. 15. okt. 16:47 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica Buys Ikerian

2025. g. 15. okt. 16:34 UTC

Tirgus saruna

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

7.74% augšup

Prognoze 12 mēnešiem

Vidējais 183.3 USD  7.74%

Augstākais 205 USD

Zemākais 160 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

12 ratings

6

Pirkt

6

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat